NCT04451174 (PREDCOVID) is a Phase 3 clinical trial of Prednisone in COVID-19, sponsored by University of Chile.

Who is sponsoring NCT04451174?

NCT04451174 is sponsored by University of Chile.

What drugs are being tested in NCT04451174?

Interventions in NCT04451174: Prednisone.

Is NCT04451174 still recruiting?

NCT04451174 is currently terminated. Last updated 3 June 2021.

Last reviewed 2021-06-03 · How we verify

NCT04451174: PREDCOVID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia

Terminated Phase 3 Last updated 3 June 2021

What this trial tests

Phase 3 trial testing Prednisone in COVID-19 in 60 participants. Terminated before completion.

Timeline

23 June 2020

Primary endpoint
30 January 2021

30 January 2021

Quick facts

Lead sponsor	University of Chile
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	60
Start date	23 June 2020
Primary completion	30 January 2021
Estimated completion	30 January 2021
Sites	1 location across Chile

Drugs / interventions tested

Prednisone (prednisone) — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

University of Chile

Who can join

Adults 18 to 90, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Steroids has shown benefits in COVID19 patients in observational studies. We hypothesized that early use of corticosteroids, low dose, in mild disease, can decrease progression to respiratory failure and death.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Systemic corticosteroids for the treatment of COVID-19.
Wagner C, Griesel M, Mikolajewska A, Mueller A, et al · · 2021 · cited 151× · PMID 34396514 · DOI 10.1002/14651858.cd014963
The intersection of COVID-19 and cancer: signaling pathways and treatment implications.
Zong Z, Wei Y, Ren J, Zhang L, et al · · 2021 · cited 54× · PMID 34001144 · DOI 10.1186/s12943-021-01363-1
Corticosteroids for COVID-19 Therapy: Potential Implications on Tuberculosis.
Gopalaswamy R, Subbian S. · · 2021 · cited 52× · PMID 33917321 · DOI 10.3390/ijms22073773
Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence.
Wagner C, Griesel M, Mikolajewska A, Metzendorf MI, et al · · 2022 · cited 44× · PMID 36385229 · DOI 10.1002/14651858.cd014963.pub2
Chemotherapy vs. Immunotherapy in combating nCOVID19: An update.
Choudhury A, Mukherjee G, Mukherjee S. · · 2021 · cited 28× · PMID 34020832 · DOI 10.1016/j.humimm.2021.05.001
Platelets in the perspective of COVID-19; pathophysiology of thrombocytopenia and its implication as prognostic and therapeutic opportunity.
Delshad M, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, Poopak B, et al · · 2021 · cited 21× · PMID 34304001 · DOI 10.1016/j.intimp.2021.107995
Early use of corticosteroids in non-critical patients with COVID-19 pneumonia (PREDCOVID): a structured summary of a study protocol for a randomised controlled trial.
Salinas M, Andino P, Palma L, Valencia J, et al · · 2021 · cited 5× · PMID 33499887 · DOI 10.1186/s13063-021-05046-6
FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities.
Hernández-Rodríguez J, Durán-Sanclemente J, Prieto-González S, Prieto-González S, et al · · 2022 · cited 1× · PMID 36173596 · DOI 10.1007/s40261-022-01201-2

Verify or expand the search:

Other trials of Prednisone

Trials testing the same drug.

NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT06738368 — Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin · Phase 2 · recruiting
NCT07493148 — Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL · Phase 2 · recruiting
NCT07278856 — Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphoma · Phase 1 · not yet recruiting

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other University of Chile trials

Trials by the same sponsor.

NCT07372417 — Macrophage/Monocyte Driven Inflammation and Anesthetic Sensitivity in Aging · not yet recruiting
NCT07254975 — An Observational Prospective Study of Anesthetic Sensitivity Assessed by Alpha Band Power and Its Association With Emerg · not yet recruiting
NCT06028854 — Blood Characteristics and Abdominal Emergency Surgery · suspended
NCT07585669 — Effects of Omega-3 Fatty Acids on Inflammation and Gut Microbiota in Celiac Disease · NA · recruiting
NCT07152171 — Pain Neuroscience Education Delivered During Aerobic Exercise Versus Exercise Alone · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04451174 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Chile
Last refreshed: 3 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04451174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing